| Literature DB >> 34884841 |
Elisa Carloni1, Adriana Ramos2, Lindsay N Hayes3.
Abstract
Many types of stressors have an impact on brain development, function, and disease susceptibility including immune stressors, psychosocial stressors, and exposure to drugs of abuse. We propose that these diverse developmental stressors may utilize a common mechanism that underlies impaired cognitive function and neurodevelopmental disorders such as schizophrenia, autism, and mood disorders that can develop in later life as a result of developmental stressors. While these stressors are directed at critical developmental windows, their impacts are long-lasting. Immune activation is a shared pathophysiology across several different developmental stressors and may thus be a targetable treatment to mitigate the later behavioral deficits. In this review, we explore different types of prenatal and perinatal stressors and their contribution to disease risk and underlying molecular mechanisms. We highlight the impact of developmental stressors on microglia biology because of their early infiltration into the brain, their critical role in brain development and function, and their long-lived status in the brain throughout life. Furthermore, we introduce innate immune memory as a potential underlying mechanism for developmental stressors' impact on disease. Finally, we highlight the molecular and epigenetic reprogramming that is known to underlie innate immune memory and explain how similar molecular mechanisms may be at work for cells to retain a long-term perturbation after exposure to developmental stressors.Entities:
Keywords: development; early life stress; ethanol; innate immune memory; maternal immune activation; microglia; stressor; tolerance; training
Mesh:
Substances:
Year: 2021 PMID: 34884841 PMCID: PMC8657756 DOI: 10.3390/ijms222313035
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Tissue and microglia (MG) phenotypes after exposure to various developmental stressors.
| Model | Tissue Phenotype | Microglia Phenotype | Reactivity | Citation | |||
|---|---|---|---|---|---|---|---|
| 2nd Stim | Response | ||||||
| MIA | Rat, E15, PIC | ↑IL-1β and TNFα (RNA) in whole Hpc | ↑MG density in NAc, ↑Iba1 (protein) in the Cb and Hpc | none | [ | Mattei 2014 | |
| MIA | Mouse, E15, PIC | ↑Tspo binding and IL-6 (protein) in whole Hpc | ↑Iba1 and CD18 (protein) in Cb and Hpc, ↓MG phagocytosis in Hpc | none | [ | Mattei 2017 | |
| MG RNA-seq: ↓genes inflammatory response, phagocytosis, and cell migration. ↑genes for synaptic plasticity, VEGF signaling, and glial cell migration | |||||||
| MIA | Rat, E15, PIC | ↑MG density and soma size in NAc and Hpc, ↑MHCII (protein) in Ctx | none | [ | Hadar 2017 | ||
| MIA | Mouse, E12 or E15, PIC | ↑MG motility (velocity) at E18, ↓MG motility (velocity) at P10 | LPS | ↑MG directional motility at P42 (after E12 MIA) | [ | Ozaki 2020 | |
| MIA | Mouse, E15–16–17, LPS | LPS | ↓IL-1β, TNFα, and IL-6 (RNA) in MG from the whole brain | [ | Schaafsma 2017 | ||
| ↑IL-1β (RNA) in MG from Hpc | |||||||
| ↑IL-1β, TNFα, and IL-6 (RNA) in whole Hpc | |||||||
| MIA | Rat, E15, PIC | At P35: ↑TNFα ↓IL-4 and IL-10 (RNA) in whole brain | LPS at P35 | ↑IL-1β, ↓IL-6, IL-4 and IL-10 (RNA) in the whole brain | [ | Clark 2019 | |
| LPS at P60 | ↓IL-6, TNFα, IFNγ, and IL-10 (RNA) in the whole brain | ||||||
| MIA | Rat, E7, E10, E13, E16, E19, LPS | ↑CD200R (RNA), ↓CD200R (protein) in FC | LPS | mild changes in gene expression of inflammatory molecules in FC and Hpc in MIA-responsive and MIA-non-responsive mice | [ | Chamera 2020 | |
| MIA | FIRS: Rat, E20, intra-amniotic LPS | LPS at P5 | ↓activated MG density, ↑IL-1β, ↓IL-6, TNFα, Cxcl10, Ccl2 (RNA) in the Hpc | [ | Singh 2021 | ||
| ELS | Rat, mild random stress, E4–20 | ↑IL-6 (RNA) in Hpc | [ | Zhang 2016 | |||
| ELS | Rat, maternal forced swim, E10–20 | ↑ramified MG density and ↓ameboid MG density | none | [ | Gomez-Gonzalez 2010 | ||
| ELS | Mouse, maternal restraint stress, E12 –E20 | ↑IL-1β (RNA) in Hpc | ↑MG density, ↑MG activated morphology | LPS | ↑IL-6, TNFα, IP10 (RNA) in the Hpc, ↑MG with activated morphology | [ | Diz-Chavez 2012 |
| ELS | Mouse, maternal restraint stress, E12 –E20 | ↑IL-1β and TNFα (RNA) in Hpc | ↑MG activated morphology in Hpc | LPS | ↑TNFα in the Hpc, ↑MG density in Hpc | [ | Diz-Chavez 2013 |
| ELS | Mouse, stress environment, E13–17 | ↑Aif1 and Tlr9 (RNA & protein) in Hpc | ↑MG density in Hpc | none | [ | Cohen 2016 | |
| ELS | Mouse, maternal restraint stress, E12 –E20 | ↑MG total density, ↑density of ameboid MG | none | [ | Bittle 2018 | ||
| ELS | Mouse, IL-1β, E12–13 | ↑MG total density, ↑density of ameboid MG | |||||
| ELS | Mouse, corticosterone, E12–13 | ↑MG total density, ↑density of ameboid MG | |||||
| ELS | Rat, 72H maternal sleep deprivation, E4, E9, or E18 | ↑IL-1β, TNFα, IL-6 (RNA), ↓IL-10 (RNA) in the Hpc | ↑MG activated morphology | none | [ | Zhao 2014 | |
| ELS | Rat, 72H maternal sleep deprivation, E18 | ↑IL-1β, TNFα, IL-6, CD68, iNOS, ↓IL-10, IL-4, Ym1, Arg1, Cd206 in the Hpc | ↑MG density, ↑Iba1 (protein) in Hpc | none | [ | Zhao 2015 | |
| ELS | Rat, 72H maternal sleep deprivation, E18 | ↑IL-1β, TNFα, IL-6, ↓IL-10, IL-4, Ym1, Arg1 in the Hpc | ↑MG density with activated morphology | none | [ | Han 2020 | |
| ELS | Mouse, maternal seperation, P1–21 | ↑MG density and MG density with activated morphology at P14, ↑MG phagocytosis at P28 in Hpc, MG RNA-seq: altered immune modulators | none | [ | Delpech 2016 | ||
| ELS | Rat, maternal separation, P1–14 | ↑IL-1β, TNFα in Hpc | ↑MG density with activated morphology | 3H maternal separation | ↑IL-1β, ↓TNFα in Hpc, ↑TNFα and IL-6 in Hypo, ↑corticosterone | [ | Roque 2016 |
| ELS | Mouse, maternal seperation, P2–14 | ↑MG motility | [ | Takasturu 2015 | |||
| ELS | Mouse, 180 min maternal separation, P1–21 | LPS | ↑Iba1 in Hpc | [ | Wu 2021 | ||
| ELS | Mouse, 15 min maternal separation, P1–21 | ↓Iba1, Nlrp3, IL-18, NFκB in the Hpc | |||||
| EtOH | Mouse, 10% drink, preconception to P21 | ↑IL-1β, Cxcl1, MCP1, MIP1α, IL-17, CD11b, and MHCII (protein) in whole Ctx | ↑Iba1 (protein) in the Ctx | none | [ | Pascual 2017 | |
| EtOH | Mouse, 3.5g/kg EtOH, P2–9 | ↑MG density in the Cb | none | [ | Kane 2011 | ||
| EtOH | Mouse, 4 g/kg EtOH, P4–9 | ↑IL-1β and TNFα (RNA) in Ctx, Hpc, and Cb | ↑MG activated morphology in the Hpc, Ctx, Cb | none | [ | Drew 2015 | |
| EtOH | Rat, 4h EtOH vapor, P3–5 | ↑IL-1β and TNFα (RNA) in Cb | ↑MG activated morphology in the Cb | none | [ | Topper 2015 | |
| EtOH | Mouse, 3–5 g/kg EtOH, P7–8 | ↑IL-1β and TNFα (RNA) in Ctx | ↑density of ameboid MG, ↑MG activated morphology, ↑Itgb2, P2ry12 (RNA), ↑CD68 (protein) in the Ctx | none | [ | Ahlers 2015 | |
| EtOH | Mouse, 2 g/kg EtOH, E6–E18 | ↑TNFα, IL-12a, IL-10 (RNA), ↓IL-6 and TGFβ (RNA) in the Ctx | ↑MG density, ↑MG activated morphology in the Ctx | none | [ | Komada 2017 | |
| EtOH | Mouse, 2.5 g/kg EtOH, P5 | ↑MCP1 and IL-6 (protein) in the spinal cord | ↑Iba1, CD68, and P2×7 (protein) in MG in the spinal cord | none | [ | Ren 2019 | |
| EtOH | Rat, 2.5 g/kg EtOH, P2–6 | ↑TNFα, MCP1, Csf1r, and TLR4 (RNA) in Hypo | ↑MG density, ↑MG activated morphology, ↑Iba1 protein intensity in the Hypo | none | [ | Shrivastava 2017 | |
| EtOH | Rat, 2.5 mg/kg EtOH, P2–6 | ↑TNFα, IL-6, Csf1r, and TLR4 (RNA) in Hypo | ↑activated MG density in the Hypo | LPS | ↑IL-6 and TNFα (RNA) in MG, ↑activated MG density in the Hypo | [ | Chastain 2019 |
Molecular mechanisms and metabolic interventions underlying innate immune memory in monocytes and microglia.
| Cell-Type | Model | Immune Paradigm | 1st Stim | Reactivity | Metabolic Intervention | Citation | ||
|---|---|---|---|---|---|---|---|---|
| 2nd Stim | Response | |||||||
|
| Human primary monocytes | Training | b-glucan | N/A | ↑ TNFα, IL-6, HIFα and mTOR pathway, ↑ glycolysis and H3K27Ac hallmark in relevant promoter regions | Training is blocked with metformin and wortmanin | [ | Cheng 2014 |
|
| Human primary monocytes | Training | b-glucan or fumarate | LPS | ↑ TNFα and IL-6, ↑ glycolysis, glutaminolysis and cholesterol synthesis | Training is blocked by metformin | [ | Arts 2016 |
|
| Tolerance | LPS | LPS | ↓ glycolysis, glutamynolysis, and cholesterol synthesis | ||||
|
| Human primary monocytes | Training | b-glucan | LPS | ↑ TNFα, ↑ glycolysis, cholesterol synthesis pathway, and TCA cycle, ↑ H3K27Ac hallamrk in relevant promoter regions | Training is blocked by fluvastatin (through cholesterol synthesis pathway) | [ | Bekkering 2018 |
|
| Training | Mevalonate | LPS | ↑ TNFα, ↑ glycolysis and TCA cycle, ↑ H3K27Ac hallamark in relevant promoter regions | ||||
|
| Human primary monocytes from patients with IgD syndrome | Training | Accumulation of mevalonate caused by mutations in mevalonate kinase | LPS | ↑ TNFα, IL1β, and IL6, ↑ glycolysis and mTOR pathway | |||
|
| Human BMDMs | Tolerance | LPS | LPS | ↓ TNFα, IL1β, IL12, and IL6 | Tolerance is blocked in the absence of Glutamine and a-ketoglutarate | [ | Liu 2017 |
|
| Human monocytes from sepsis patients | Tolerance | Sepsis | LPS | Trancriptomic data determined ↓ of ample array of inflammatory interleukines and chemokines. Although their expression is ↑ at basal levels (w/o LPS stimulation) | [ | Shalova 2015 | |
|
| PBMCs from chronic mucocutaneous candidiais patients | Impaired Training | STAT1 mutation | b-glucan, LPS | Equal TNFα and IL-6 as stimulated control | [ | Ifrim 2015 | |
|
| PBMCs from hyper- immunoglobulinaemia E syndrome | Training | STAT3 mutation | b-glucan, LPS | ↑ TNFα, IL6 | |||
|
| Human primary monocytes from LPS exposed human | Tolerance | LPS | LPS | Epigenetic and transcriptomic data determined ↓ signatures of permissive hallmarks | [ | Novakovick 2016 | |
|
| Human primary monocytes from LPS exposed human | Impaired Tolerance | LPS | b-glucan+LPS | Epigenetic and transcriptomic data determined ↑ signatures of permissive marks | |||
|
| Human primary monocytes | Training | b-glucan | LPS | Epigenetic and transcriptomic data determined ↑ signatures of permissive marks | |||
|
| Human primary monocytes | Tolerance | LPS | LPS | Epigenetic and transcriptomic data determined ↓ signatures of permissive hallmarks | |||
|
| PBMCs from patients with sepsis | Tolerance | Sepsis | LPS | ↓ TNFα, IL1β, and IL-6, ↓ glycolysis | IFNγ (rescued tolerance) | [ | Cheng 2016 |
|
| APP23 mice | Training | 1×LPS | AD model/ Ab amyloid accumulation | ↓ IL-10 in brain, ↓ accumulation of Aβ, Epigenetic and transcriptomic data determined an involvement of HIFα, and ↑ signature of permissive marks | [ | Wendeln 2018 | |
|
| Tolerance | 4×LPS | AD model/ Ab amyloid accumulation | ↓ IL-1β in brain, ↑ accumulation of Ab, Epigenetic and transcriptomic data determined ↓ signature of permissive marks | ||||
|
| Stroke mouse model | Training | 1×LPS | Ischemia | ↑ IL-1β, ↓ IL-10 in brain, Epigenetic and transcriptomic data determined an involvement of HIFa and ↑ signature of permissive marks | |||
|
| Tolerance | 4×LPS | Ischemia | ↓ IL-1β in brain | ||||
|
| Mouse primary microglia culture | Training | 1×Ab | ↑ IL-1β, ↑ glycolysis and ↓ TCA | [ | Baik 2019 | ||
|
| Mouse Primary microglia culture | Tolerance | 3×Ab | ↓ IL-1β, ↓ glycolysis | ||||
|
| 5×FAD mice | Tolerance | Endogenous Ab aggregates | Aβ iv injection | ↓ IL-1β, TNFα, and CCL2 among others, ↓ motility | |||
|
| 5×FAD mice | Impaired Tolerance | Intervention with IFNγ | ↑ TNFα, ↑ glycolysis, ↑ phagocytic capacity | IFNγ (rescued tolerance) | |||
|
| Mouse primary microglia | Training | Low dose LPS | LPS | ↑ TNFα and IL-6 | [ | Lajqi 2019 | |
|
| Training | b-dectin | LPS | ↑ TNFα and IL-6 | ||||
|
| Tolerance | High dose LPS | LPS | ↓ TNFα and IL-6 | ||||
|
| P6–P12 mouse pups | Training | Low dose LPS | LPS | ↑ TNFα, IL-6, IL-1β, iNOS | [ | Lajqi 2020 | |
|
| Adult mice | Training | Low dose LPS | LPS | ↑ TNFα, IL-6, IL-1β, iNOS | |||
|
| Aging mice | Ablated Training | Low dose LPS | LPS | Equal TNFα, IL-6, IL-1β, iNOs as in stimulated control | |||
|
| P6–P12 mouse pups | Tolerance | High dose LPS | LPS | ↓ TNFα, IL-6, IL-1β, iNOS | |||
|
| Adult mice | Tolerance | High dose LPS | LPS | ↓ TNFα, IL-6, IL-1β, iNOS | |||
|
| Aging mice | Impaired Tolerance | High dose LPS | LPS | Equal TNFα, IL-6, IL-1β, iNOS as in stimulated control | |||
|
| Mouse primary microglia culture | Tolerance | LPS | LPS | ↓ IL-1β, TNFα, IL-6 | Tolerance is Relb mediated | [ | Schaafsma 2015 |
|
| Wild type mice | Tolerance | LPS | LPS | ↓ IL-1β, TNFα, IL-6 | Tolerance is Relb mediated | ||
|
| Wild type mice | Tolerance | LPS | LPS | Epigenetic and transcriptomic data determined ↓ signatures of permissive marks | [ | Zhang 2021 | |
|
| Ercc1 KO mice | Training | Aging | LPS | Epigenetic and transcriptomic data determined ↑ signatures of permissive marks | |||